Literature DB >> 28439747

Management of Cirrhotic Patients After Successful HCV Eradication.

Ryan M Kwok1, Tram T Tran2.   

Abstract

OPINION STATEMENT: Chronic hepatitis C (HCV) is a hepatotropic virus which, when untreated, can lead to progressive inflammation and fibrosis resulting in cirrhosis, hepatocellular carcinoma (HCC), and decompensations related to end-stage liver disease. The relatively recent introduction of all oral, interferon-free, direct-acting antiviral medications against HCV has transformed the management of these patients. Previous treatment regimens were prolonged, poorly tolerated, and frequently did not result in cure. Current therapies achieve sustained viral response (SVR) in the vast majority of patients including those with decompensated liver disease; a previously challenging population to treat. These successes will result in significant numbers of cirrhotic patients requiring management after SVR. Although many complications of cirrhosis are improved in this setting, regular follow-up of HCC, esophageal varices, and other sequelae of cirrhosis will be necessary. This chapter will review the management of cirrhosis in HCV patients achieving cure.

Entities:  

Keywords:  Ascites; Cirrhosis; Decompensated liver disease; Gastroesophageal varices; Hepatic encephalopathy; Hepatitis C; Hepatocellular carcinoma; Portal hypertension; Sustained virologic response

Year:  2017        PMID: 28439747     DOI: 10.1007/s11938-017-0134-2

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  48 in total

1.  Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.

Authors:  Jagpreet Chhatwal; Sumeyye Samur; Brian Kues; Turgay Ayer; Mark S Roberts; Fasiha Kanwal; Chin Hur; Drew Michael S Donnell; Raymond T Chung
Journal:  Hepatology       Date:  2017-01-06       Impact factor: 17.425

2.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

Review 3.  Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies.

Authors:  Salvatore Petta; Marcello Maida; Fabio Salvatore Macaluso; Marco Barbara; Anna Licata; Antonio Craxì; Calogero Cammà
Journal:  Gastroenterology       Date:  2015-09-18       Impact factor: 22.682

4.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.

Authors:  Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

5.  Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis.

Authors:  Javier P Gisbert; Luisa García-Buey; José María Pajares; Ricardo Moreno-Otero
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

6.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.

Authors:  J P Iredale; R C Benyon; J Pickering; M McCullen; M Northrop; S Pawley; C Hovell; M J Arthur
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

7.  Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study.

Authors:  Chia-Yen Dai; Wan-Long Chuang; Chi-Kung Ho; Ming-Yen Hsieh; Jee-Fu Huang; Li-Po Lee; Nai-Jen Hou; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Jun-Fa Tsai; Wen-Yu Chang; Ming-Lung Yu
Journal:  J Hepatol       Date:  2008-04-22       Impact factor: 25.083

8.  Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen.

Authors:  Martina Gambato; Sofía Pérez-Del-Pulgar; Charlotte Hedskog; Evguenia S Svarovskia; Diana Brainard; Jill Denning; Michael P Curry; Michael Charlton; Noelia Caro-Pérez; Maria Carlota Londoño; George Koutsoudakis; Xavier Forns
Journal:  Gastroenterology       Date:  2016-07-01       Impact factor: 22.682

Review 9.  Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review.

Authors:  Sirio Fiorino; Letizia Bacchi-Reggiani; Dario de Biase; Adele Fornelli; Michele Masetti; Andrea Tura; Fabio Grizzi; Matteo Zanello; Laura Mastrangelo; Raffaele Lombardi; Giorgia Acquaviva; Luca di Tommaso; Arrigo Bondi; Michela Visani; Sergio Sabbatani; Laura Pontoriero; Carlo Fabbri; Andrea Cuppini; Annalisa Pession; Elio Jovine
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  2 in total

1.  Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes.

Authors:  Divya Ramnath; Katharine M Irvine; Samuel W Lukowski; Leigh U Horsfall; Zhixuan Loh; Andrew D Clouston; Preya J Patel; Kevin J Fagan; Abishek Iyer; Guy Lampe; Jennifer L Stow; Kate Schroder; David P Fairlie; Joseph E Powell; Elizabeth E Powell; Matthew J Sweet
Journal:  JCI Insight       Date:  2018-07-26

2.  Evaluation of health status in patients with hepatitis c treated with and without interferon.

Authors:  R Ragusa; G Bertino; A Bruno; E Frazzetto; F Cicciu; G Giorgianni; L Lupo
Journal:  Health Qual Life Outcomes       Date:  2018-01-17       Impact factor: 3.186

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.